nplate header

Article

body { color: #000000; /* color: #002F65; */ background-color:#f5f5f5; } table { background-color:#FFFFFF; text-align:left; font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; } p, div { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; } h3 { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight:bold; } a { color:#3e7ebc; } a:hover { text-decoration:underline } p { margin:10px 0px 10px 0px; } ol, ul{ list-style: none; padding-left:0px; } .header-link { font-size: 13px; font-weight: bold; color: #C41230; text-decoration:none } .mainbody { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; padding: 10px 30px 10px 30px; } .otherbody { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; color: #000000; } .blue-link { color: #002F65; text-decoration: underline; } .blue-bold-link { color: #002F65; text-decoration: underline; font-size: 13px; font-weight: bold; } .red-header { font-size: 13px; font-weight: bold; color: #C41230; } .smbullet-item { background-image:url(sm-bullet.gif); } .bullet-item { background-color: transparent; background-image: url("http://imaging.ubmmedica.com/all/cn/infocenter/chronic-itp/bullet.gif"); background-repeat: no-repeat; background-attachment: scroll; background-position: 0pt 2px; padding-top: 0pt; padding-right: 0pt; padding-bottom: 15px; padding-left: 20px; margin-bottom: 12px; margin-left:25px } li { list-style:disc; padding-top: 0pt; padding-right: 0pt; padding-bottom: 5px; padding-left: 5px; margin-bottom: 0px; margin-left:25px } #bulletItems li { list-style: none; background-color: transparent; background-image: url("http://imaging.ubmmedica.com/all/cn/infocenter/chronic-itp/bullet.gif"); background-repeat: no-repeat; background-attachment: scroll; background-position: 0pt 5px; padding-top: 0pt; padding-right: 0pt; padding-bottom: 5px; padding-left: 20px; margin-bottom: 0px; margin-left:15px } #bulletItems p, .tan { color: #E8D4A3 } .resBox { width: 250px; border-left-width-value: 1px; border-left-style-value: solid; border-left-color-value: #d3d3d3; border-right-width-value: 1px; border-right-style-value: solid; border-right-color-value: #d3d3d3; padding-top: 0px; padding-right: 10px; padding-bottom: 0px; padding-left: 10px; text-align: left; word-wrap: break-word; } #wrapper { width:100%; padding:0px; margin:0px; text-align:center; } /************************ ***** DO NOT EDIT ******/#container { /*width: 80%;*/ width: 300px; margin-right: auto; margin-left: auto; text-align: left; background-color: #FFFFFF;}/* Bar Graphs */.graph { width: 280px; position: relative; right: 16px;}.bar-title { position: relative; float: left; width: 140px; line-height: 20px; margin-right: 12px; font-weight: bold; text-align: right; color: #C41230;}.bar-container { position: relative; float: left; width: 120px; height: 10px; margin: 0px 0px 15px;}.bar-container div { background-color:#c61130; height: 20px;}.bar-container strong { position: absolute; right: 0; top: 0px; overflow: hidden;}#poll-results p { clear: both; text-align: center;}#poll-container { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size:11px; background: #ffffff url(/blank-theme/images/custom/poll-bg-top.png) 0 0 no-repeat; padding: 16px 24px 16px 16px; line-height: 14px;}#poll-bottom { height: 12px; width: 300px; background: #ffffff url(/blank-theme/images/custom/poll-bg-bottom.png) bottom left no-repeat;}#poll-container input { margin: 8px 4px 0;}#poll-container label { color: #C41230; font-weight: bold;}#poll-container p { color: black; line-height: 20px; padding-top: 5px; padding-right: 5px; padding-bottom: 5px; padding-left: 5px;}#poll-container h3 { margin: 8px;}input#pollbutton { width: 78px; height: 30px; float: right; margin: 10px -4px -10px 0; border: 0 none; cursor: pointer; display: inline; background: transparent url(/blank-theme/images/custom/poll-button.png) top left no-repeat;}/***************************** END DO NOT EDIT *****/

CancerNetwork Home

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
7 experts are featured in this series.
Related Content